CA2581606A1 - Carrier-free composition for the treatment of onychomycosis - Google Patents
Carrier-free composition for the treatment of onychomycosis Download PDFInfo
- Publication number
- CA2581606A1 CA2581606A1 CA002581606A CA2581606A CA2581606A1 CA 2581606 A1 CA2581606 A1 CA 2581606A1 CA 002581606 A CA002581606 A CA 002581606A CA 2581606 A CA2581606 A CA 2581606A CA 2581606 A1 CA2581606 A1 CA 2581606A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- ingredients
- carrier
- mixture
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
A composition for the treatment of onychomycosis (fungal nail disease) is described. The composition consists essentially of thymol, camphor, menthol and Eucalyptus citridiora as a colorless liquid oil without any carrier or solvent for these ingredients.
Description
CARRIER-FREE COMPOSITION FOR THE TREATMENT
OF ONYCHOMYCOSIS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] Not Applicable STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
OF ONYCHOMYCOSIS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] Not Applicable STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
[0002] Not Applicable STATEMENT REGARDING GOVERNMENT RIGHTS
[0003] Not Applicable BACKGROUND OF THE INVENTION
(1) Field of the Invention [0004] The present invention relates to a carrier-free composition which is an onychomycosis (fungal nail disease) therapeutic agent. In particular, the present invention relates to a composition consisting essentially of thymol, camphor, menthol and Eucalyptus citridiora oil.
(2) Description of the Related Art [0005] U.S. Patent No. 6,344,190 to Nair et al describes the use of camphor, menthol, eucalyptus and thymol with a carrier which is a solvent for the ingredients;
particularly, an ester of an alcohol such as isoamyl alcohol. This was done to solubilize the ingredients. It was thought that the carrier was necessary for this purpose.
OBJECTS
(1) Field of the Invention [0004] The present invention relates to a carrier-free composition which is an onychomycosis (fungal nail disease) therapeutic agent. In particular, the present invention relates to a composition consisting essentially of thymol, camphor, menthol and Eucalyptus citridiora oil.
(2) Description of the Related Art [0005] U.S. Patent No. 6,344,190 to Nair et al describes the use of camphor, menthol, eucalyptus and thymol with a carrier which is a solvent for the ingredients;
particularly, an ester of an alcohol such as isoamyl alcohol. This was done to solubilize the ingredients. It was thought that the carrier was necessary for this purpose.
OBJECTS
[0006] It is therefore an object of the present invention to provide a carrier-free composition wherein the ingredients are solubilized to provide a clear solution. It is further an object of the present invention to provide a method for the preparation of the composition. It is also an object of the present invention to provide a method for the use of the composition. These and other objects will become increasingly apparent by reference to the following description.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[0007] The present invention relates to a composition which consists essentially of (1) thymol, (2) camphor, (3) menthol and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier. Preferably, the composition contains equal parts by weight of the ingredients. Further, the composition of the colorless liquid has been provided by a method which comprises stirring ingredients (1) to (3) into ingredient (4) to provide the colorless liquid. Still further, the composition of the ingredients (1) to (3) are introduced into ingredient (4) and then the mixture is heated to produce the colorless liquid. Preferably, the composition of the mixture has been heated up to about 80 C.
[0008] Further, the present invention relates to a method for the preparation of a pharmaceutical composition which comprises: mixing (1) thymol, (2) camphor, and (3) menthol into (4) Eucalyptus citridiora oil; and treating the mixture to provide a colorless oil. Preferably, the present invention relates to the method wherein the treating is by heating the mixture. Still further, the present invention relates to the method wherein the treating is by mixing the ingredi,ents over a period of time to provide the colorless mixture.
[0009] Further still, the present invention relates to a method of treating toenail fungal infections which comprises: applying a composition which consists essentially of (1) thymol, (2) camphor, (3) menthol, and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier.
Preferably, the method of the composition contains equal parts of the ingredients.
Preferably, the method of the composition contains equal parts of the ingredients.
[0010] The substance and advantages of the present invention will become increasingly apparent by reference to the following description.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] Equal weights of thymol, camphor, menthol and Eucalyptus citridiora oil were used to formulate the TNF
therapeutic agent resulting to a clear liquid that penetrates the cuticles and nails. The Eucalyptus citridiora oil was weighed first and stirred with equal weights of solid thymol, menthol and camphor. The mixture was then warmed to 80 C till it forms a colorless liquid or stir at room temperature till the solids dissolve to form a colorless.liquid. The resulting product is easy to apply on infected nails using a nail polish applicator or by a cotton swab.
therapeutic agent resulting to a clear liquid that penetrates the cuticles and nails. The Eucalyptus citridiora oil was weighed first and stirred with equal weights of solid thymol, menthol and camphor. The mixture was then warmed to 80 C till it forms a colorless liquid or stir at room temperature till the solids dissolve to form a colorless.liquid. The resulting product is easy to apply on infected nails using a nail polish applicator or by a cotton swab.
[0012] Tests were performed with the composition on toenail fungi as follows:
[0013] Components in the formulation were equal weights of the following compounds 1-4:
1. Camphor OH
2. Menthol 3. Thymol 4. E. citridiora oil [0014] Microbial cultures. All organisms, except the Fusarium and Candida spp., were purchased from American Type Culture Collection (ATCC), Manassas, Virginia, USA. The Fusarium and Candida spp. were Michigan State University (MSU) strains (Nair, M.G., Putnam, A.R., Mishra, S.K., Mulks, M.H., Taft, W.H., Keller, J.E., Miller, J.R., Zhu, P.P., Meinhart, J.D., Lynn, D.G. 1989. Fae,riefungin: A new broad-spectrum antibiotic from Streptomyces griseus var.
autotrophicus. J Nat Prod 52: 797-809).
1. Camphor OH
2. Menthol 3. Thymol 4. E. citridiora oil [0014] Microbial cultures. All organisms, except the Fusarium and Candida spp., were purchased from American Type Culture Collection (ATCC), Manassas, Virginia, USA. The Fusarium and Candida spp. were Michigan State University (MSU) strains (Nair, M.G., Putnam, A.R., Mishra, S.K., Mulks, M.H., Taft, W.H., Keller, J.E., Miller, J.R., Zhu, P.P., Meinhart, J.D., Lynn, D.G. 1989. Fae,riefungin: A new broad-spectrum antibiotic from Streptomyces griseus var.
autotrophicus. J Nat Prod 52: 797-809).
[0015] Antimicrobial assay.M. canis (ATCC 42888), E.
floccosum (ATCC 44685), F. oxysporum (MSU strain), F.
proliferatum (MSU strain), A. chrysogenum (ATCC 22571), A.
strictum (ATCC 46646), A. terreus (ATCC 52293), and A.
flavus (ATCC 60040) were cultured in Petri dishes containing PDA medium (20 mL). T. rubrum (ATCC 28202), T.
mentagrophytes (ATCC 42194), S. brevicaulis (ATCC 36139), and S. dimidiatum (ATCC 46921) were cultured in Petri dishes containing Emmon's modification of Sabouraud's agar medium (20 mL). S. hyalinum (ATCC 66093) was cultured in Petri dishes containing Malt extract agar medium (20 mL).
The test organisms C. albicans (MSU strain), C. kruseii (MSU
strain), and C. parapsilosis (MSU strain) were cultured in Petri dishes containing YMG media (20 mL).
floccosum (ATCC 44685), F. oxysporum (MSU strain), F.
proliferatum (MSU strain), A. chrysogenum (ATCC 22571), A.
strictum (ATCC 46646), A. terreus (ATCC 52293), and A.
flavus (ATCC 60040) were cultured in Petri dishes containing PDA medium (20 mL). T. rubrum (ATCC 28202), T.
mentagrophytes (ATCC 42194), S. brevicaulis (ATCC 36139), and S. dimidiatum (ATCC 46921) were cultured in Petri dishes containing Emmon's modification of Sabouraud's agar medium (20 mL). S. hyalinum (ATCC 66093) was cultured in Petri dishes containing Malt extract agar medium (20 mL).
The test organisms C. albicans (MSU strain), C. kruseii (MSU
strain), and C. parapsilosis (MSU strain) were cultured in Petri dishes containing YMG media (20 mL).
[0016] The cells from a fully- grown plate of each organism were suspended in saline solution (5 mL) and diluted to obtain 5 x 106 CFU/mL using a hemacytometer. 50 ~L of this suspension was used to inoculate I mL of respective growth medium of each test organism. Test formulation was added to the inoculated tubes at concentrations ranging from 250 to 5 ~1/mL. The tubes containing cell cultures and compounds were incubated at 27 C for 72- 96 h. At the end of the incubation period, the tubes were examined for growth of the organism and further monitored for 7 days after which they were recorded for growth or no growth. The concentration at which no growth was observed or minimum concentration for 100 % inhibition (MIC loo) is shown in Table 1 for each organism.
Table 1. MICIoo ( g/mL) for the mixture containing equal weights of camphor, menthol, thymol and Eucalyptus citriodora oil against organisms causing onychomycosis.
Organism MIC
>20 Acremonium chrysogenunz A. strictum >_20 AspergilZus flavus >30 _30 A. terreus Candida albicans' _50 C. kruseii >_50 C. parapsilosis >_50 Epidernzoplzyton floccosum ?30 Fusarium oxysporum ?30 F. proliferatum >_30 Microsporum canis ?40 _30 Scopulariopsis brevicaulis >_30 Scytalidium dinzidiatum S. hyalinum >_30 Trichophyton mentagroplZytes ~:30 T. rubruni >_30 [0017] The composition had a very broad spectrum of activity as can be seen from the results.
Table 1. MICIoo ( g/mL) for the mixture containing equal weights of camphor, menthol, thymol and Eucalyptus citriodora oil against organisms causing onychomycosis.
Organism MIC
>20 Acremonium chrysogenunz A. strictum >_20 AspergilZus flavus >30 _30 A. terreus Candida albicans' _50 C. kruseii >_50 C. parapsilosis >_50 Epidernzoplzyton floccosum ?30 Fusarium oxysporum ?30 F. proliferatum >_30 Microsporum canis ?40 _30 Scopulariopsis brevicaulis >_30 Scytalidium dinzidiatum S. hyalinum >_30 Trichophyton mentagroplZytes ~:30 T. rubruni >_30 [0017] The composition had a very broad spectrum of activity as can be seen from the results.
[0018] It is intended that the foregoing description be only illustrative of the present invention and that the present invention be limited only by the hereinafter appended claims.
Claims (10)
1. A composition which consists essentially of (1) thymol, (2) camphor, (3) menthol and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier.
2. The composition of Claim 1 wherein the composition contains equal parts by weight of the ingredients.
3. The composition of Claims 1 or 2 wherein the colorless liquid has been provided by stirring ingredients (1) to (3) into ingredient (4) to provide the colorless liquid.
4. The composition of Claims 1 or 2 wherein the ingredients (1) to (3) are introduced into ingredient (4) and then the mixture is heated to produce the colorless liquid.
5. The composition of Claims 1 or 2 wherein the mixture has been heated up to about 80°C.
6. A method for the preparation of a pharmaceutical composition which comprises:
(a) mixing (1) thymol, (2) camphor, and (3) menthol into (4) Eucalyptus citridiora oil; and (b) treating the mixture to provide a colorless oil.
(a) mixing (1) thymol, (2) camphor, and (3) menthol into (4) Eucalyptus citridiora oil; and (b) treating the mixture to provide a colorless oil.
7. The method of Claim 6 wherein the treating is by heating the mixture.
8. The method of Claim 6 wherein the treating is by mixing the ingredients over a period of time to provide the colorless mixture.
9. A method of treating toenail fungal infections which comprises:
applying a composition which consists essentially of (1) thymol, (2) camphor, (3) menthol, and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier.
applying a composition which consists essentially of (1) thymol, (2) camphor, (3) menthol, and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier.
10. The method of Claim 9 wherein the composition contains equal parts of the ingredients.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2004/031630 WO2006036144A1 (en) | 2004-09-24 | 2004-09-24 | Carrier-free composition for the treatment of onychomycosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2581606A1 true CA2581606A1 (en) | 2006-04-06 |
Family
ID=36119190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002581606A Abandoned CA2581606A1 (en) | 2004-09-24 | 2004-09-24 | Carrier-free composition for the treatment of onychomycosis |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1796703A4 (en) |
| JP (1) | JP2008514596A (en) |
| CA (1) | CA2581606A1 (en) |
| WO (1) | WO2006036144A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL1036661C2 (en) | 2009-03-04 | 2010-09-07 | Serrix B V | Anti-fungal compounds & compositions. |
| DE202010012041U1 (en) | 2010-08-31 | 2010-11-18 | Sanderstrothmann Gmbh | Preparation for nail care |
| CN103893599A (en) * | 2014-04-12 | 2014-07-02 | 张军 | External traditional Chinese medicine lotion for treating onychomycosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04154719A (en) * | 1990-10-19 | 1992-05-27 | Hiroshi Kikuchi | Athlete's foot drug |
| TR200000110T2 (en) * | 1997-05-30 | 2000-08-21 | The Procter & Gamble Company | Disinfecting compositions and methods of disinfecting surfaces. |
| JP2000128800A (en) * | 1998-10-16 | 2000-05-09 | Hideyo Yamaguchi | Prevention of infection of dermatophytosis and/or its treatment and tool and material for treatment |
| US6344190B1 (en) * | 1999-02-08 | 2002-02-05 | Board Of Trustees Of Michigan State University | Method and compositions for treatment of fungal nail disease |
| US6436424B1 (en) * | 2000-03-20 | 2002-08-20 | Biosphere Medical, Inc. | Injectable and swellable microspheres for dermal augmentation |
| JP2003073290A (en) * | 2001-08-31 | 2003-03-12 | Kao Corp | External preparation composition |
-
2004
- 2004-09-24 JP JP2007533444A patent/JP2008514596A/en active Pending
- 2004-09-24 CA CA002581606A patent/CA2581606A1/en not_active Abandoned
- 2004-09-24 EP EP04789085A patent/EP1796703A4/en not_active Withdrawn
- 2004-09-24 WO PCT/US2004/031630 patent/WO2006036144A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006036144A1 (en) | 2006-04-06 |
| EP1796703A1 (en) | 2007-06-20 |
| JP2008514596A (en) | 2008-05-08 |
| EP1796703A4 (en) | 2009-07-01 |
| AU2004323577A1 (en) | 2006-04-06 |
| WO2006036144A8 (en) | 2007-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Chemical composition, antibacterial activity and study of the interaction mechanisms of the main compounds present in the Alpinia galanga rhizomes essential oil | |
| US10980846B2 (en) | Use of gram negative species to treat atopic dermatitis | |
| Ramsewak et al. | In vitro antagonistic activity of monoterpenes and their mixtures against ‘toe nail fungus’ pathogens | |
| Khosravi et al. | Zataria multiflora cream for the treatment of acute vaginal candidiasis | |
| US7341747B2 (en) | Carrier-free composition for the treatment of onychomycosis | |
| Osborne et al. | Antifungal drug response in an in vitro model of dermatophyte nail infection | |
| US10653727B2 (en) | Use of gram negative species to treat atopic dermatitis | |
| Soares et al. | In vitro activity of antifungal and antiseptic agents against dermatophyte isolates from patients with tinea pedis | |
| Kotnik et al. | Terbinafine hydrochloride treatment of Microsporum canis experimentally-induced ringworm in cats | |
| Ansari et al. | Design and evaluation of topical herbal antifungal stick containing extracts of Rhinacanthus nasutus | |
| Kanimozhi et al. | Screening and evaluation of potential antifungal plant extracts against skin infecting fungus Trichophyton rubrum | |
| CA2581606A1 (en) | Carrier-free composition for the treatment of onychomycosis | |
| Gayatri et al. | Novel thiazolinyl-picolinamide-based palladium (II) complex extenuates the virulence and biofilms of vulvovaginal candidiasis (VVC) causing Candida | |
| EP2429289A2 (en) | Compositions and products containing cycloaliphatic diol antimicrobial agents and methods of using the compositions and products | |
| AU2004323577B2 (en) | Carrier-free composition for the treatment of onychomycosis | |
| CN112451406B (en) | Plant source multi-effect composition and preparation method and application thereof | |
| WO2022058952A1 (en) | Use of a preservative composition to preserve the eubiosis of skin tissue and scalp | |
| Shehu et al. | Nano-Enhanced Ointment Formulation: Optimizing Synthesis, Physicochemical Properties and Antimicrobial Efficacy | |
| CN115427015A (en) | Compositions and methods for microbial treatment of skin disorders | |
| ALAHMAD et al. | IN VITRO ANTIFUNGAL ACTIVITY OF THYME OIL AGAINST CANDIDA ALBICANS ISOLATED FROM NAIL FUNGUS (ONYCHOMYCOSIS) | |
| Abdul-Hussain et al. | Crude aqueous Proteus mirabilis extract with quorum sensing inhibitory activity can increase the susceptibility of multidrug resistant Pseudomonas aeruginosa to antimicrobials | |
| Amani et al. | In vitro Inhibition of Candida Species by Aqueous Garlic Extract in Gel and Lotion: Problem of Stability | |
| Al-Toma0T et al. | The preparation and Evaluation of Some Metronidazole Formulations as Gels and The study of Their Medicinal Activities Against Pathogenetic Microorganisms Causing Dermatitides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |